Biotech: Page 2


  • Image attribution tooltip
    Stock via Getty Images

    What now? Alzheimer's drugmakers ponder the path to approval

    Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

    By Kelly Bilodeau • April 14, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: iSpecimen's Jill Mullan

    Need biospecimens? iSpecimen aims to be the Amazon of research materials, and Jill Mullan is changing the game.

    By April 13, 2022
  • Image attribution tooltip
    Yongyuan via Getty Images
    Q&A

    Biotech goes Hollywood

    A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

    By April 13, 2022
  • Image attribution tooltip
    iStock via Getty Images

    'Bootcamp' helps rare disease advocates learn the ropes of drug development

    Ultragenyx’s CEO on why supporting others in rare diseases pays dividends all around.

    By Kim Ribbink • April 12, 2022
  • Image attribution tooltip
    Ilya Lukichev via Getty Images

    Optinose CEO senses big opportunities for the company's nasal delivery device

    Peter Miller explains how a repackaged sinus drug has won late-stage clinical success.

    By Jared Whitlock • April 11, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Lyell Immunopharma's Liz Homans

    The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

    By April 6, 2022
  • Image attribution tooltip
    Permission granted by Alnylam/Yvonne Greenstreet
    Profile

    Seeing yourself at the top: Alnylam CEO on why representation matters

    Dr. Yvonne Greenstreet became just the sixth woman in the world to head up a biopharma company with a market cap of more than $5 billion when she took on the role of CEO in January.

    By Alexandra Pecci • April 6, 2022
  • Image attribution tooltip

    Permission granted by Apurva Saraf. 

    An analyst turned pharma CEO learns the art of operations

    Under Apurva Saraf’s guidance, Cosette Pharmaceuticals is pivoting wholeheartedly into the cardio space.

    By Jared Whitlock • April 5, 2022
  • Image attribution tooltip
    Justin Sullivan via Getty Images

    Clinical trial recruitment hits the local pharmacy counter

    CVS Health's partnership with clinical trial software company Medable is designed to make recruitment easier for patients and drug makers alike.

    By Kelly Bilodeau • April 5, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    Time-saving tech lights Alcon's path into digital innovation

    Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

    By Kim Ribbink • April 4, 2022
  • Image attribution tooltip

    Sangamo Therapeutics

    Q&A

    Sangamo has its finger on the next evolution of gene editing

    Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

    By March 31, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Daré Bioscience's Sabrina Martucci Johnson

    The CEO is setting a path to transform women’s health at an opportune time.

    By March 30, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up

    A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.

    By Kelly Bilodeau • March 23, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    Why Astellas is adopting a 'focus area approach' to partnerships

    Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

    By Kim Ribbink • March 22, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Psychedelics without the party: Inside MindMed's LSD makeover

    MindMed’s CEO, Robert Barrow, on the company’s latest moves to ‘change the world’ with psychedelics.

    By Alexandra Pecci • March 21, 2022
  • Image attribution tooltip
    Retrieved from PharmaVOICE on March 21, 2022
    Q&A

    BioMarin's new global head of advocacy is tackling the holy grail of patient engagement

    In her new role, Dr. Roz is keeping her patient-first approach.

    By March 21, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Attralus' medical officer believes systemic amyloidosis could be 'solvable'

    Gregory Bell is not just aiming to treat amyloidosis, but eventually cure it.

    By Robin Robinson • March 18, 2022
  • Image attribution tooltip
    Stock via Getty Images

    COVID-19 trials aren't the only studies that can achieve super speed

    Is it possible to enroll clinical trials 10 times faster than the industry’s average speed? Elligo Health Research thinks so.

    By Kelly Bilodeau • March 15, 2022
  • Image attribution tooltip

    Image courtesy of Medigene.

    Q&A

    Medigene's CEO on striking a collaboration deal with BioNTech

    The two companies recently announced a $29 million collaboration. 

    By Jared Whitlock • March 15, 2022
  • Image attribution tooltip

    Permission granted by Sanjeev Luther.

    Q&A

    Clearing hurdles in rare cancer drug development

    Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

    By Kim Ribbink • March 14, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

    The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

    By March 14, 2022
  • Image attribution tooltip
    Permission granted by Terry Weber
    Q&A

    Biote CEO: Employers need to normalize women's health issues in the workforce

    A survey by Biote reveals the impact of menopause on working women.

    By Robin Robinson • March 14, 2022
  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Q&A

    Ultragenyx's CEO on building a 'next-gen' rare disease company

    How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

    By Kim Ribbink • March 9, 2022
  • Image attribution tooltip

    Permission granted by Russell Potterfield.

    Profile

    From angel to operator: The unlikely journey of Endevica Bio's CEO

    Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.

    By Jared Whitlock • March 9, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Genentech's Quita Highsmith

    Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.

    By March 9, 2022